IONS vs ORKA: stock comparison and AI forecast
Ionis Pharmaceuticals Inc (IONS) and Oruka Therapeutics, Inc. (ORKA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
IONS Ionis Pharmaceuticals Inc
- Price
- $39.42 -48.1% · 6M
- Market Cap
- $6.55B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
ORKA Oruka Therapeutics, Inc.
- Price
- $102.86 +60.5% · 6M
- Market Cap
- $6.81B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- IONS and ORKA have similar market capitalizations ($6.55B and $6.81B).
- Over the last six months ORKA returned +60.5% and IONS -48.1%.
- IONS carries 5.81 times debt per unit of equity, against 0.02 times for ORKA.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | IONS | ORKA |
|---|---|---|
| Market Cap | $6.55B | $6.81B |
| P/B Ratio | 14.90x | 6.11x |
| EPS | $-3.77 | $-4.15 |
| Book Value/Share | $2.65 | $16.83 |
| Revenue/Share | $1.60 | – |
| FCF/Share | $-3.37 | $-1.53 |
Profitability & Margins
| Metric | IONS | ORKA |
|---|---|---|
| ROE | -128.5% | – |
| ROA | -18.9% | – |
| ROIC | -22.2% | -13.9% |
| Gross Margin | 94.0% | – |
| Operating Margin | -224.0% | – |
| Net Margin | -213.0% | – |
| EBT Margin | -211.8% | – |
| Tax Rate | -0.6% | – |
Financial Health
| Metric | IONS | ORKA |
|---|---|---|
| Current Ratio | 7.89x | 38.51x |
| Quick Ratio | 7.73x | – |
| D/E Ratio | 5.81x | 0.02x |
| Financial Leverage | 6.81x | 1.02x |
| Interest Coverage | -22.1x | -15.9x |
| Working Capital | $2.18B | $862M |
Cash Flow
| Metric | IONS | ORKA |
|---|---|---|
| Operating Cash Flow | -$496M | -$101M |
| Free Cash Flow | -$561M | -$101M |
| Capital Spending | -$64M | -$230K |
| FCF/Sales | -211.4% | – |
| CapEx/Sales | 24.3% | – |
Operational Efficiency
| Metric | IONS | ORKA |
|---|---|---|
| Asset Turnover | 0.09x | – |
| Inventory Turnover | 0.3x | – |
| Fixed Assets Turnover | 1.7x | – |
| Days Inventory | 1158 days | – |
| Payables Period | 1087 days | – |
Income Statement
| Metric | IONS | ORKA |
|---|---|---|
| Total Revenue | $265M | – |
| Operating Income | -$594M | -$155M |
| Net Income | -$565M | – |
| R&D Expense | – | $129M |
| SG&A Expense | $528M | – |
| Cost of Goods Sold | $16M | – |
Dividend & Shareholder Information
| Metric | IONS | ORKA |
|---|---|---|
| Shares Outstanding | 166M | 66M |
IONS vs ORKA: stock comparison and AI forecast
Which is bigger, IONS or ORKA?
IONS and ORKA have similar market capitalizations ($6.55B and $6.81B).
Which stock performed better over the last six months, IONS or ORKA?
Over the last six months ORKA returned +60.5% and IONS -48.1%.
Which one does Intratio's AI model rank higher, IONS or ORKA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.